Quadrant Capital Group LLC Biotechnology

Quadrant Capital Group LLC

$3 Billion
Q3 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
KURA Kura Oncology, Inc.	$749M	$16,000 0.0% of portfolio	1,834	Q3 2025 New
ADMA Adma Biologics, Inc.	$3.06B	$14,000 0.0% of portfolio	972	Q3 2025 Reduced 94.17%
RCUS Arcus Biosciences, Inc.	$1.45B	$14,000 0.0% of portfolio	1,079	Q3 2025 New
RVMD Revolution Medicines, Inc.	$5.94B	$14,000 0.0% of portfolio	317	Q3 2025 New
URGN Uro Gen Pharma Ltd.	$553M	$13,000 0.0% of portfolio	688	Q3 2025 New
CRSP Crispr Therapeutics Ag	$4.32B	$12,000 0.0% of portfolio	194	Q3 2025 New
PHAT Phathom Pharmaceuticals, Inc.	$575M	$12,000 0.0% of portfolio	1,073	Q3 2025 New
PRTA Prothena Corp Public LTD CO	$481M	$12,000 0.0% of portfolio	1,260	Q3 2025 New
DNLI Denali Therapeutics Inc.	$2.34B	$11,000 0.0% of portfolio	782	Q3 2025 New

HRMY Harmony Biosciences Holdings, Inc.	$2.01B	$11,000 0.0% of portfolio	424	Q3 2025 New
JAZZ Jazz Pharmaceuticals PLC	$8.84B	$11,000 0.0% of portfolio	84	Q3 2025 New
FOLD Amicus Therapeutics, Inc.	$2.66B	$10,000 0.0% of portfolio	1,350	Q3 2025 New
CELC Celcuity Inc.	$1.38B	$10,000 0.0% of portfolio	206	Q3 2025 New
NUVB Nuvation Bio Inc.	$1.06B	$10,000 0.0% of portfolio	2,853	Q3 2025 New
QURE Uni Qure N.V.	$1.4B	$10,000 0.0% of portfolio	187	Q3 2025 New
VCYT Veracyte, Inc.	$2.82B	$10,000 0.0% of portfolio	298	Q3 2025 New
CRNX Crinetics Pharmaceuticals, Inc.	$2.34B	$9,000 0.0% of portfolio	230	Q3 2025 New
KALV Kal Vista Pharmaceuticals, Inc.	$328M	$9,000 0.0% of portfolio	777	Q3 2025 New

ARVN Arvinas, Inc.	$562M	$8,000 0.0% of portfolio	987	Q3 2025 New
TERN Terns Pharmaceuticals, Inc.	$846M	$8,000 0.0% of portfolio	1,165	Q3 2025 New
ABCL Ab Cellera Biologics Inc.	$1.05B	$7,000 0.0% of portfolio	1,429	Q3 2025 New
TRVI Trevi Therapeutics, Inc.	$661M	$7,000 0.0% of portfolio	789	Q3 2025 New
XNCR Xencor Inc	$891M	$7,000 0.0% of portfolio	638	Q3 2025 New
BCRX Biocryst Pharmaceuticals Inc	$1.32B	$5,000 0.0% of portfolio	705	Q3 2025 New
CGEM Cullinan Oncology, Inc.	$390M	$5,000 0.0% of portfolio	904	Q3 2025 New
SANA Sana Biotechnology, Inc.	$759M	$5,000 0.0% of portfolio	1,480	Q3 2025 New
CLDX Celldex Therapeutics, Inc.	$1.2B	$4,000 0.0% of portfolio	160	Q3 2025 New
RYTM Rhythm Pharmaceuticals, Inc.	$5.54B	$4,000 0.0% of portfolio	42	Q3 2025 New
RARE Ultragenyx Pharmaceutical Inc.	$2.32B	$4,000 0.0% of portfolio	136	Q3 2025 New
ABEO Abeona Therapeutics Inc.	$26.5M	$3,000 0.0% of portfolio	667	Q3 2025 New
APLS Apellis Pharmaceuticals, Inc.	$2.23B	$3,000 0.0% of portfolio	169	Q3 2025 New
KROS Keros Therapeutics, Inc.	$445M	$3,000 0.0% of portfolio	251	Q3 2025 New
IMVT Immunovant, Inc.	$3.55B	$2,000 0.0% of portfolio	80	Q3 2025 New
MIRM Mirum Pharmaceuticals, Inc.	$2.63B	$2,000 0.0% of portfolio	31	Q3 2025 New
CDXC Chroma Dex Corp.	$420M	$2,000 0.0% of portfolio	471	Q3 2025 New
RZLT Rezolute, Inc.	$385M	$2,000 0.0% of portfolio	248	Q3 2025 New
ACAD Acadia Pharmaceuticals Inc	$3.89B	$1,000 0.0% of portfolio	56	Q3 2025 New
ABUS Arbutus Biopharma Corp	$678M	$1,000 0.0% of portfolio	277	Q3 2025 New
ACLX Arcellx, Inc.	$3.94B	$1,000 0.0% of portfolio	14	Q3 2025 New
CPRX Catalyst Pharmaceuticals, Inc.	$2.38B	$1,000 0.0% of portfolio	80	Q3 2025 New
CMPX Compass Therapeutics, Inc.	$494M	$1,000 0.0% of portfolio	405	Q3 2025 New
EYPT Eye Point Pharmaceuticals, Inc.	$404M	$1,000 0.0% of portfolio	100	Q3 2025 New
INSM Insmed Inc	$26.2B	$1,000 0.0% of portfolio	12	Q3 2025 New
RGNX Regenxbio Inc.	$498M	$1,000 0.0% of portfolio	126	Q3 2025 New
VIR Vir Biotechnology, Inc.	$747M	$1,000 0.0% of portfolio	182	Q3 2025 New
XOMA Xoma Corp	$371M	$1,000 0.0% of portfolio	35	Q3 2025 New
FDMT 4 D Molecular Therapeutics, Inc.	$351M	$0 0.0% of portfolio	95	Q3 2025 New
ADCT Adc Therapeutics Sa	$307M	$0 0.0% of portfolio	173	Q3 2025 New
AGIO Agios Pharmaceuticals, Inc.	$2.39B	$0 0.0% of portfolio	16	Q3 2025 New
ALDX Aldeyra Therapeutics, Inc.	$296M	$0 0.0% of portfolio	185	Q3 2025 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Quadrant Capital Group LLC, based on Form 13F filings with the SEC.

News

Stay updated on Quadrant Capital Group LLC with notifications on news.